Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chugai Pharmaceutical CoTSE:4519 +1.16%96 PEG Ratio is 2.16 as of Jul. 17, 2026, which is 19% above its 10-year median of 1.82. GuruFocus rates TSE:4519 with a GF Score™ of 96/100 and a GF Value™ of 円7,744.25 (Fairly Valued). The stock has 1 warning sign investors should review. Among 348 Drug Manufacturers companies, Chugai Pharmaceutical Co ranks worse than 56.32% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Chugai Pharmaceutical Co's PEG Ratio or its related term are showing as below:
TSE:4519'
s PEG Ratio Range Over the Past 10 Years
Min: 0.31 Med: 1.82 Max: 21.73
Current: 2.15
During the past 13 years, Chugai Pharmaceutical Co's highest PEG Ratio was 21.73. The lowest was 0.31. And the median was 1.82.
TSE:4519's PEG Ratio is ranked worse than 56.32% of 348
companies
in the Drug Manufacturers industry
Industry Median: 1.715
vs TSE:4519: 2.15
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Chugai Pharmaceutical Co (TSE:4519) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Chugai Pharmaceutical Co PEG Ratio Related Terms
Chugai Pharmaceutical Co PEG Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Chugai Pharmaceutical Co's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chugai Pharmaceutical Co PEG Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Chugai Pharmaceutical Co's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Chugai Pharmaceutical Co's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Chugai Pharmaceutical Co (TSE:4519) has a PEG Ratio of 2.16 as of Jul. 17, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Chugai Pharmaceutical Co and its competitors. This is 19% above median its historical median of 1.82. Over the past decade, Chugai Pharmaceutical Co's PEG Ratio has ranged from 0.31 to 21.73. According to the industry distribution chart, Chugai Pharmaceutical Co ranks #196 out of 348 companies in the Drug Manufacturers industry, placing it in the top 56.3%.
Is Chugai Pharmaceutical Co's PEG Ratio too high?
Chugai Pharmaceutical Co's current PEG Ratio of 2.16 is 19% above median its 10-year median of 1.82. Over the past 10 years, this metric has ranged from a low of 0.31 to a high of 21.73. The Drug Manufacturers industry median PEG Ratio is 1.72. Chugai Pharmaceutical Co's value of 2.16 is 25.9% above this industry median. Based on the distribution chart, Chugai Pharmaceutical Co ranks #196 out of 348 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Chugai Pharmaceutical Co has a GF Score™ of 96/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Chugai Pharmaceutical Co's PEG Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Chugai Pharmaceutical Co ranks #196 out of 348 companies for PEG Ratio. This places Chugai Pharmaceutical Co in the lower half of its industry. The industry median PEG Ratio is 1.72. Chugai Pharmaceutical Co's value of 2.16 is 25.9% above this benchmark. Historically, Chugai Pharmaceutical Co's own PEG Ratio has ranged from 0.31 to 21.73 over the past decade. While the company's 10-year median is 1.82 vs. the industry median of 1.72, Chugai Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Drug Manufacturers company?
The median PEG Ratio among Drug Manufacturers companies is 1.72, based on 348 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chugai Pharmaceutical Co's current PEG Ratio of 2.16 is 25.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Chugai Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median PEG Ratio is 1.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chugai Pharmaceutical Co's current PEG Ratio is 2.16, which is 19% above median its own 10-year median of 1.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chugai Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Chugai Pharmaceutical Co (TSE:4519) is currently considered Fairly Valued. The stock's GF Value™ is 円7,744.25, compared to a current price of 円7,325.00 — trading 5.4% below its estimated fair value. The current PEG Ratio is 2.16, which is 19% above median its 10-year median of 1.82 and 25.9% above the Drug Manufacturers industry median of 1.72. Chugai Pharmaceutical Co's overall GF Score™ is 96/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Chugai Pharmaceutical Co (TSE:4519), the current PEG Ratio is 2.16 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chugai Pharmaceutical Co (TSE:4519) Overvalued in 2026?
Based on GuruFocus' analysis, Chugai Pharmaceutical Co stock appears to be undervalued.
The current stock price of 円7,325.00 is trading 5.4% below its estimated GF Value™ of 円7,744.25.
GuruFocus considers Chugai Pharmaceutical Co to be Fairly Valued.
Key valuation signals for TSE:4519:
PEG Ratio: 2.16 (19% above median its 10-year median of 1.82)
GF Value™: 円7,744.25 vs. price of 円7,325.00 (5.4% below fair value)
Industry Position: 25.9% above the Drug Manufacturers median (#196 of 348)
No single metric tells the full story. See the TSE:4519 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra (hemophilia), Actemra (rheumatoid arthritis, covid), Foundayo (oral obesity pill), and Nemluvio (atopic dermatitis, prurigo nodularis).
96GF Score
Get the complete analysis for TSE:4519
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4519 has been successfully added to your 
